Varlilumab

{
  "id": "MLC-T-ONC-017462",
  "term": "Varlilumab",
  "field": "Oncology and biomedicine",
  "definition": "A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of CDX-1127, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation.",
  "synonyms": [
    "anti-CD27 monoclonal antibody CDX-1127",
    "immunoglobulin G1, anti-(human CD antigen CD27) (human monoclonal CDX1127 clone 1f5 heavy chain), disulfide with human monoclonal CDX-1127 clone 1f5 kappa chain, dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/varlilumab/"
}